Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

43 results about "Receptor potential" patented technology

A receptor potential, also known as a generator potential, a type of graded potential, is the transmembrane potential difference produced by activation of a sensory receptor. A receptor potential is often produced by sensory transduction. It is generally a depolarizing event resulting from inward current flow. The influx of current will often bring the membrane potential of the sensory receptor towards the threshold for triggering an action potential. Receptor potential can work to trigger an action potential either within the same neuron or on an adjacent cell. Within the same neuron, a receptor potential can cause local current to flow to a region capable of generating an action potential by opening voltage gated ion channels. A receptor potential can also cause the release of neurotransmitters from one cell that will act on another cell, generating an action potential in the second cell. The magnitude of the receptor potential determines the frequency with which action potentials are generated, and is controlled by adaption, stimulus strength, and temporal summation of successive receptor potentials. Receptor potential relies on receptor sensitivity which can adapt slowly, resulting in a slowly decaying receptor potential or rapidly, resulting in a quickly generated but shorter lasting receptor potential.

Compositions and methods for mode-selective modulation of transient receptor potential vanilloid-1 (TRPV1)

PCT designated stageWO2026006328A1Organic chemistryHeterocyclic compound active ingredientsSelective modulationClinical trial
TRPV1 is an integral cation channel widely expressed in various tissues and involved in critical biological functions, such as thermosensation. It is polymodally activated by distinct stimuli, including chemical ligands, heat, and protons (pH). However, dozens of clinical trials targeting various types of TRPV1 -mediated pain have generally failed, primarily due to hyperthermia (increased body temperature). Meta-analysis of clinical data suggests that mode-selectivity is essential to realizing the therapeutic potential of TRPV1. TRPV1 is regulated allosterically, with vanilloids and other chemical ligands binding to the voltage-sensing-like domain (VSLD), resulting in the gating of the pore domain. Therefore, compositions and methods for modulating TRPV1 to treat human pathophysiologies, such as pain, are described herein.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA +1

Active agent modulating the activity of an ion channel for use in regulation of skin pigmentation

Active agents are used for actively controlling and / or treating skin pigmentation in subjects without undesired side effects by activating, enhancing, inactivating, blocking or dampening the cellular response of the transient receptor potential ion channel TRPM5 or interfering with the expression of the ion channel.
Owner:CUTANEON SKIN & HAIR INNOVATIONS GMBH

Oral nicotine composition and product thereof

PendingCN120982780ATobacco treatmentReceptor potentialNicotine
Embodiments of the present invention provide an oral nicotine composition and a product thereof, the oral nicotine composition comprising: a nicotine component, an active component that can be used to block nicotinic acetylcholine receptor and / or transient receptor potential ion channels, and lecithin, the lecithin is matched with the active component which can be used for blocking a nicotine acetylcholine receptor and / or transient receptor potential ion channel, so that nicotine stimulation, especially stomach stimulation, can be effectively relieved, and discomfort symptoms such as heartburn, hiccup and stomachache of a user are avoided.
Owner:SHENZHEN HUABAO COLLABORATIVE INNOVATION TECH RES INST CO LTD

Five-membered 3-aryloxyl-3-heteroaryl propylamine compound, and crystalline form and use thereof

UndeterminedES3075814T3ArylDisease
The present invention relates to a five-membered 3-aryloxy-3-heteroarylpropylamine compound, its crystalline form, and its use. Specifically, the present invention provides a compound, or a pharmaceutically acceptable salt or prodrug thereof, having the structure of Formula I. The compound, or the pharmaceutically acceptable salt or prodrug of the present invention, possesses excellent inhibitory function against the transient receptor potential (TPR) channel protein and good therapeutic function for TPR-associated diseases.
Owner:SHANGHAI LEADO PHARMATECH CO LTD (100 00)

Compounds for treatment of excitotoxicity

PCT designated stageWO2026060489A1Nervous disorderOrganic chemistrySensory potentialTRPC
The present invention relates to modulators of canonical-type of transient receptor potential (TRPC) channels, compositions thereof, and methods therewith. The present invention also relates to methods of treating TRPC mediated conditions using such modulators.
Owner:NYRADA PTY LTD

Application of multiple promoters capable of efficiently targeting on ON-type bipolar cells in gene therapy technology

The invention relates to the technical field of biology and the technical field of gene therapy. The invention relates to a retina light-donating bipolar cell specific promoter sequence and application thereof to regulation and control of expression of therapeutic genes in retina or retina organoid cells in a gene therapy technology so as to improve and / or recover vision. The retina bipolar cells are divided into light-supplying activated bipolar cells (ON type bipolar cells or depolarized bipolar cells) and light-removing activated bipolar cells (OFF type bipolar cells or hyperpolarized bipolar cells), and accurate and specific expression of transgenosis is realized by utilizing gene differential expression characteristics of different types of bipolar cells. The efficient and accurate treatment on the retina diseases is realized. The promoter has the advantage that the promoter of the transient receptor potential cation channel protein (TRPM1) gene with high-level and high-specificity expression can be realized in light-activated bipolar cells.
Owner:ZHONGMOU MEDICAL TECH (WUHAN) CO LTD

Application of anacycline A in preparation of analgesic drugs

The invention relates to application of anacycline A in preparation of analgesic drugs, in particular to an anacycline A compound separated from anacycline roots. The compound can be applied to analgesic drugs with inhibition effects on transient receptor potential cation channel subfamily M member 8 (TRPM8), a voltage-gated potassium ion channel 1.2 (Kv1.2), a voltage-gated potassium ion channel 1.3 (Kv1.3), transient receptor potential cation channel protein 6 (TRPC6) and a voltage-gated calcium ion channel 2.1 (Cav2.1), in particular to drugs for neuropathic pain, traumatic pain or inflammatory pain. The compound anacycline A can be combined with a plurality of analgesia-related targets, so that a synergistic effect is generated, the treatment effect is enhanced, and meanwhile, side effects and drug resistance are reduced.
Owner:XINJIANG TECH INST OF PHYSICS & CHEM CHINESE ACAD OF SCI +1

3-aryloxy-3-five-membered heteroaryl propylamine compound, and crystal form and use thereof

A 3-aryloxyl-3-five-membered heteroaryl propylamine compound, and crystal form and use thereof are provided. Specifically, a compound, or a pharmaceutically acceptable salt or a prodrug thereof, the compound having a structure of formula I is described. The compound, or pharmaceutically acceptable salt or prodrug thereof has an excellent inhibition function for a transient receptor potential channel protein (TPR), and has a good treatment function for diseases associated with the TPR.
Owner:SHANGHAI LEADO PHARMATECH CO LTD

Oral antagonist compositions for nicotine burning relief

The invention relates to oral analgesic compositions for alleviation of perceived nicotine irritation through inhibition or blocking of nicotine activated receptors or ion channels in the gastrointestinal tract, including the oral cavity. The composition of the invention comprises one or more nicotine sources, one or more buffering agents, and at least two antagonists in an effective amount to inhibit or block nicotine agonist activation of Nicotinic Acetylcholine Receptors (nAChR) and / or Transient Receptor Potential (TRP) ion channels, the at least two antagonists being selected from the group consisting of a first antagonist comprising camphor or one or more compounds resembling camphor, a second antagonist comprising eucalyptol, and a third antagonist comprising (1R,2S,5R)—N-(4-Methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexanecarboxamide (WS-12).
Owner:FERTIN PHARMA AS

Riboswitches for regulating gene expression and therapeutic methods of using the same

PCT designated stage expiredWO2024227074A9VectorsPeptide/protein ingredientsHeterologousEnzyme Gene
The present disclosure provides an expression cassette comprising from 5' to 3': (i) promoter, (ii) an upstream exon, (iii) an upstream intron, (iv) an alternatively spliced exon comprising a translation initiation sequence, (v) a downstream intron, (vi) a downstream exon, and (vii) a heterologous nucleic acid sequence. In some aspects, the upstream exon, the upstream intron, the alternatively spliced exon, the downstream intron, and the downstream exon, each comprise a portion of a gene selected from the group consisting of a Transient Receptor Potential Cation Channel Subfamily V Member 3 (TRPV3) gene, a Serine / Threonine Kinase 31 (STK31) gene, an Ubiquitin Specific Peptidase 25 (USP25) gene, a IK gene, a Testis Expressed 14, Intercellular Bridge Forming Factor (TEX14) gene, a General Transcription Factor IIB (GTF2B) gene, and a LY6 / PLAUR Domain Containing 3 (LYPD3) gene.
Owner:KRIYA THERAPEUTICS INC

Treatment for hot flushes

PendingUS20250186375A1Pharmaceutical delivery mechanismAmide active ingredientsTransient receptor potential channelChannel blocker
Disclosed herein are methods for treating hot flushes in a subject. In one embodiment, treating hot flushes includes administering to a subject in need of such treatment, a therapeutically effective amount of a transient receptor potential channel (TRP channel) blocker or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods for amelioration, alleviation, or prevention of the thermal discomfort in hot flushes, comprising: selecting a subject in need of treatment for hot flushes, administering to the subject a therapeutically effective amount of a TRP channel blocker, such as a TRPV1 blocker, or a pharmaceutically acceptable salt thereof.
Owner:DIGNITY HEALTH

Transient receptor potential vanilloid 6 inhibitors

The present invention relates to methods and uses of preventing or treating cancer The method or use may comprise administration of a cancer therapy together with a compound of Formula (I). In the compound of Formula (I) A is a substituted heteroaryl comprising at least one ring nitrogen; and D includes an optionally substituted: phenyl, N-linked 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, N-linked 10H-phenoxazinyl, indole, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl or thienyl (or R3' and D together form a five or six membered ring). The compound of Formula (I) may be an inhibitor of transient receptor potential vanilloid 6 (TRPV6). The cancer therapy may be a chemotherapeutic agent. The present invention also relates to pharmaceutical compositions and kits comprising a compound of Formula (I) and / or a chemotherapeutic agent.
Owner:UNIQUEST PTY LTD

Application of alkylamine compound

PendingCN121818599ANervous disorderAntipyreticTransient receptor potential channelPharmaceutical drug
The invention relates to application of alkylamine compounds. Specifically, the invention provides an application of a compound shown as a formula I, or an optical isomer thereof, or a raceme thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, the compound, or the optical isomer thereof, or the raceme thereof, or the solvate thereof, or the pharmaceutically acceptable salt thereof are used for preparing a pharmaceutical composition or a preparation, and the pharmaceutical composition or the preparation is used for (a) inhibiting transient receptor potential channel protein; (b) treating diseases related to transient receptor potential channel protein, in the formula, each group is defined as in the specification. (I).
Owner:NINGBO LIDAO PHARMACEUTICAL TECHNOLOGY CO LTD

Compositions and Methods for Treating Cardiovascular Diseases and Disorders

Disclosed herein are compounds and ligands, and compositions formed therewith, that treat insulin resistance-induced physiological disorders by modulating G-protein coupled receptor (GPCR) and transient receptor potential (TRP) ion channel activity. Also disclosed herein are methods for using the compositions to treat cardiovascular disorders, such as atherosclerosis.
Owner:OLFACTIVE AI INC

Preparation method for and crystal form of 3-aryloxy-3-five-membered heteroaryl-propylamine compound

ActiveUS12492195B2AntipyreticAnalgesicsArylTransient receptor potential channel
Provided are a compound as represented by formula I, a preparation method therefor, and a hydrochloride crystal form A thereof. The compound as represented by formula I and the hydrochloride crystal form A thereof have excellent inhibitory effects on transient receptor potential (TRP) channels, and have good therapeutic effects on TRP channel-associated diseases.
Owner:ZHANGZHOU PIEN TZE HUANG PHARM +1

Transient receptor potential vanilloid 6 inhibitors

The present invention relates to a method for preventing or treating cancer and its use therefor. The method or use may include administering a cancer therapy together with a compound of Formula (I). In the compound of Formula (I), A is a substituted heteroaryl containing at least one ring nitrogen, and D includes optionally substituted phenyl, N-linked 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, N-linked 10H-phenoxazinyl, indole, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl, or thienyl (or R3' and D together form a 5- or 6-membered ring). The compound of Formula (I) may be an inhibitor of transient receptor potential vanilloid 6 (TRPV6). The cancer therapy may be a chemotherapeutic agent. The present invention also relates to pharmaceutical compositions and kits containing the compound of Formula (I) and / or a chemotherapeutic agent. TIFF2026502807000127.tif30170
Owner:UNIQUEST PTY LTD

Topical formulation to decrease skin inflammation or redness

PendingUS20250170085A1Cosmetic preparationsHair cosmeticsInflammatory dermatosisAcropustulosis
Topical compositions including β-alanine and a transient receptor potential cation channel subfamily M (melastatin) member 8 (TRPM8) agonist, such as menthol, are disclosed. Also disclosed are methods of decreasing skin inflammation or redness in a subject, and methods of decreasing frequency or duration of symptoms of inflammatory skin conditions, such as rosacea.
Owner:UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION

Compositions and Methods for Treating Endocrine Diseases and Disorders

Disclosed herein are compounds and ligands, and compositions formed therewith, which modulate insulin secretion, suppress appetite, and reduce body mass by activating G-protein coupled receptors (GPCRs), such as ectopic olfactory receptors, and transient receptor potential (TRP) ion channels. Also disclosed herein are methods for using the compositions to treat endocrine diseases, such as type-2 diabetes and obesity.
Owner:OLFACTIVE AL INC

Transient receptor potential melastatin 2 (TRPM2) modulators and uses thereof

The present invention relates to modulators that inhibit the interaction between protein kinase C y (PKCy) and transient receptor potential melastatin 2 (TRPM2), including peptides, polypeptides, and small molecules, and their use in treatment of neurological and cardiovascular diseases.
Owner:UNIV OF CONNECTICUT

Transient receptor potential vanilloid 6 inhibitors

The present invention relates, inter alia, to compounds, pharmaceutical compositions of the compounds, and uses of the compounds for inhibiting transient receptor potential channel family, vanilloid subfamily member 6 (TRPV6). The compounds are of formula (I), where A is a substituted heteroaryl containing at least one ring nitrogen, and D includes optionally substituted phenyl, N-linked 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, N-linked 10H-phenoxazinyl, indole, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl, or thienyl (or R3' and D together form a 5- or 6-membered ring). The compounds may be used to treat or prevent one or more of cancer, respiratory disease, ulcerative colitis, skin disorders, bone disease, hypocalcemia, and kidney calcium stones. TIFF2026502801000601.tif28170
Owner:UNIQUEST PTY LTD

Active agent modulating the activity of an ion channel for use in inhibition of skin aging

Active agents are used for treating skin aging in subjects without undesired side effects by activating, enhancing, or positively modulating the cellular response of the transient receptor potential ion channel TRPM5 or increasing the expression of the ion channel.
Owner:CUTANEON SKIN & HAIR INNOVATIONS GMBH

Compounds for treatment of excitotoxicity

PendingUS20260152495A1Organic active ingredientsNervous disorderSensory potentialTRPC
The present invention relates to modulators of canonical-type of transient receptor potential (TRPC) channels, compositions thereof, and methods therewith. The present invention also relates to methods of treating TRPC mediated conditions using such modulators.
Owner:NYRADA PTY LTD

Substituted propionic acid derivatives and uses thereof

PendingCN121824350AOrganic chemistryNervous disorderDiseaseTransient receptor potential channel
The invention relates to substituted propionic acid derivatives and uses thereof. Specifically, the invention provides an application of a compound as shown in a formula A, or an optical isomer or a raceme thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, the compound, or the optical isomer or the raceme thereof, or the solvate thereof, or the pharmaceutically acceptable salt thereof are used for preparing a pharmaceutical composition or a preparation, and the pharmaceutical composition or the preparation is used for (a) inhibiting transient receptor potential channel protein; (b) treating diseases related to transient receptor potential channel protein, in the formula, each group is defined as in the specification. A.
Owner:NINGBO LIDAO PHARMACEUTICAL TECHNOLOGY CO LTD

TRPV2 antagonists

ActiveUS12370185B2Aerosol deliveryOintment deliveryReceptor potentialAntagonist
This invention relates to the finding that Piperlongumine compounds, such as Piperlongumine and analogues, derivatives and prodrugs thereof, are reversible, allosteric antagonists of transient receptor potential vanilloid 2 channel (TRPV2). Methods of treatment of conditions that are characterised by TRPV2 expression using Piperlongumine compounds and Piperlongumine compounds for use in such treatments are provided.
Owner:FUNDAÇÃO GIMM- GULBENKIAN INSTITUTE FOR MOLECULAR MEDICINE

Use of anagalline a in the preparation of analgesic drugs

The application relates to application of anagirine A in preparation of analgesic drugs, and relates to an anagirine A compound separated from anagallis arvensis, which is an analgesic drug with inhibitory effects on transient receptor potential cation channel subfamily M member 8 (TRPM8), voltage-gated potassium channel 1.2 (Kv1.2), voltage-gated potassium channel 1.3 (Kv1.3), transient receptor potential cation channel protein 6 (TRPC6) and voltage-gated calcium channel 2.1 (Cav2.1), and is specifically a drug for neuropathic pain, traumatic pain or inflammatory pain. The compound anagirine A in the application can be combined with multiple analgesic related target points, so that a synergistic effect is generated, the treatment effect is enhanced, and side effects and drug resistance are reduced.
Owner:XINJIANG TECH INST OF PHYSICS & CHEM CHINESE ACAD OF SCI +1

Transient receptor potential vanilloid 6 inhibitors

The invention relates to a method and application for preventing or treating cancer. The methods or uses may include administering a compound of formula (I) and cancer therapy. In the compound of formula (I), A is a substituted heteroaryl group comprising at least one cyclic nitrogen; d comprises, optionally substituted: phenyl, N-linked 3, 4-dihydro-2H-benzo [b] [1, 4] oxazinyl, N-linked 10H-phenoxazinyl, indole, pyridyl, pyrimidinyl, pyrazolo [1, 5-a] pyridyl, or thienyl (or R3'and D together form a 5-or 6-membered ring). The compound of formula (I) may be an inhibitor of transient receptor potential vanilloid 6 (TRPV6). The cancer therapy may be a chemotherapeutic agent. The invention also relates to pharmaceutical compositions and kits comprising a compound of formula (I) and / or a chemotherapeutic agent.
Owner:UNIQUEST PTY LTD